# US 2016/0354453 A1 · Compositions for generating immune tolerance by targeting erythrocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354453 A1
- Document ID: US20160354453A1
- Status: Published application
- Kind: A1
- Application number: 15/232,714
- Filed: 2016-08-09
- Published: 2016-12-08
- Earliest claimed: 2010-08-10
- Assignees: Ecole Polytechnique Federale De Lausanne (Epfl)
- Applicants: École Polytechnique Fédérale de Lausanne (EPFL)
- Inventors: Jeffrey A. Hubbell; Stephan Kontos; Karen Y. Dane
- Web page: https://patentgrep.com/patent/US20160354453A1

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/513: {Organic macromolecular compounds; Dendrimers}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6815: {Enzymes}
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/62: Insulins
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12N 9/82: Asparaginase {(3.5.1.1)}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 305/01001: Asparaginase (3.5.1.1)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/6031: {Proteins}
- A61K 2039/605: {MHC molecules or ligands thereof}
- A61K 2039/6056: {Antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- C07K 2319/22: containing a Strep-tag
- C07K 2319/23: containing a GST-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/41: containing a Myc-tag
- C07K 2319/43: containing a FLAG-tag
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

## Claims

### Claim 1

(canceled)

### Claim 2

A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising:
an antigen that results in an unwanted immune response upon administration of the antigen to a subject and recognition of the antigen by an immune cell;
wherein said antigen comprises Factor VIII;
an erythrocyte-binding moiety,
wherein said erythrocyte-binding moiety comprises a peptide ligand, an antibody fragment, or a single chain variable fragment derived from an antibody,
wherein the antigen is fused with the erythrocyte-binding moiety;
wherein said erythrocyte-binding moiety does not specifically bind to other blood components other than glycophorin-A;
wherein said composition is suitable for intravenous delivery to the subject;
wherein said erythrocyte-binding moiety has the ability to non-covalently bind an erythrocyte in situ in blood; and
wherein said binding results in the antigen being presented to the immune system and results in antigen-specific tolerance.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the erythrocyte-binding moiety comprises a peptide ligand, wherein multiple copies of the erythrocyte-binding moiety are directly fused to the antigen at a plurality of sites on the antigen, and wherein said erythrocyte-binding moiety has a dissociation constant of between about 10 μM and 0.1 nM as determined by equilibrium binding measurements between the peptide and erythrocytes.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the erythrocyte-binding moiety comprises an antibody fragment.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the antibody fragment is derived from a 10F7 clone.

### Claim 6 (depends on 2)

The composition of claim 2, wherein the erythrocyte-binding moiety comprises a peptide ligand selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

### Claim 7 (depends on 2)

The composition of claim 2, wherein the erythrocyte-binding moiety is fused to the antigen at the N- or C-terminus of the antigen.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the erythrocyte-binding moiety is capable of binding said glycophorin A with an affinity generating a dissociation constant of between about 10 μM and 0.1 nM as determined by equilibrium binding measurements between the erythrocyte-binding moiety and erythrocytes.

### Claim 9 (depends on 2)

The composition of claim 2, wherein the erythrocyte-binding moiety comprises an antibody, antibody fragment or single chain variable fragment derived from a hybridoma that produces an antibody against an erythrocyte.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the erythrocyte-binding moiety is an affinity matured antibody fragment.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the erythrocyte-binding moiety comprises a single chain variable fragment that is affinity matured and derived from a 10F7 clone.

### Claim 12

A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising:
an antigen selected from the group consisting of Factor VIII and fragments thereof, the antigen being chemically conjugated with at least one erythrocyte-binding moiety, an immune system of the subject being able to respond to or previously having responded to the antigen with an unwanted immune response,
said erythrocyte-binding moiety having the ability to non-covalently bind an erythrocyte surface in situ in blood and present said antigen to the immune system of the subject as self,
wherein said erythrocyte-binding moiety comprises a protein or peptide ligand,
wherein said erythrocyte-binding moiety does not specifically bind to other blood components, and
wherein the erythrocyte-binding moiety has a dissociation constant of between about 10 μM and 0.1 nM as determined by equilibrium binding measurements between the erythrocyte-binding moiety and erythrocytes.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the erythrocyte-binding moiety comprises a peptide ligand, wherein multiple copies of the erythrocyte-binding moiety are conjugated to the antigen at a plurality of sites on the antigen.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the peptide ligand is selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

### Claim 15 (depends on 12)

The composition of claim 12, wherein the erythrocyte-binding moiety has the ability to bind to an erythrocyte surface molecule selected from the group consisting of Band 3 (CD233), glycophorin-A, glycophorin B (CD235b), glycophorin C(CD235c), and glycophorin D (CD235d).

### Claim 16 (depends on 12)

The composition of claim 12, wherein the protein comprises an antibody fragment, wherein the antibody fragment is derived from a 10F7 clone, and wherein the antibody fragment is capable of binding human glycophorin A.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the antibody fragment has undergone affinity maturation.

### Claim 18

A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising:
an antigen fused or chemically conjugated with an erythrocyte-binding moiety;
said antigen comprising a therapeutic protein or peptide;
said antigen being recognizable by an immune system of a subject, the immune system of the subject being able to respond to or previously having responded to the antigen with an unwanted immune response,
said erythrocyte-binding moiety having the ability to non-covalently, specifically bind an erythrocyte surface in situ in blood and present said antigen to the immune system of the subject, and
wherein said erythrocyte-binding moiety comprises a peptide, an antibody, or an antibody fragment.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the therapeutic protein or peptide is Factor VIII, wherein the antigen is fused with the erythrocyte-binding moiety, and wherein the erythrocyte-binding moiety is derived from a 10F7 clone.

### Claim 20 (depends on 18)

The composition of claim 18, wherein the erythrocyte-binding moiety has the ability to bind Band 3 or glycophorin A with an affinity generating a dissociation constant of between about 10 μM and 0.1 nM as determined by equilibrium binding measurements between the erythrocyte-binding moiety and erythrocytes.

### Claim 21 (depends on 18)

The composition of claim 18, wherein the erythrocyte-binding moiety comprises a peptide ligand and wherein multiple copies of the erythrocyte-binding moiety are conjugated to the antigen at a plurality of sites on the antigen.
